#China #Series C Funding #Alebund #renal therapies #Yangzhou

Alebund Pharmaceuticals Secures Significant Funding for Kidney Disease Treatments

Alebund Pharmaceuticals, a biopharmaceutical company based in China, has successfully closed its Series C financing, raising an impressive RMB 550 million. This milestone marks a critical step in the company’s ongoing commitment to developing pioneering treatments for chronic kidney diseases and related conditions. The funding round saw participation from key investors - including the Yangzhou Guojin Investment Group Co. LTD and Kingray Capital.

Targeting a Growing Health Crisis

Chronic kidney disease (CKD) has emerged as a significant global health challenge, with increasing incidence rates each year. Alebund positions itself strategically to combat this issue by building a diverse pipeline focused on developing therapies for various renal conditions. The company’s product lineup includes treatments for CKD complications, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD).

Financing Details and Future Directions

The newly acquired financing will facilitate Alebund in accelerating the clinical development of its leading drug candidates. A major focus will be the new drug application (NDA) process for the innovative iron-based phosphate binder, AP301, as well as a global pivotal study. Furthermore, they plan to conduct phase 2 studies for their first-in-class pan phosphate transporter inhibitor, AP306, in both the U.S. and China. The fund will also bolster the commercial expansion of Mircera® within the Chinese market.

Infrastructure and Commercial Strategy

Alebund's recent advancements include the construction of a state-of-the-art small molecule production facility in Yangzhou, which is now operational. In line with its ambitious plans, the company has established a dedicated commercial team in China, focusing on promoting Mircera® and preparing for future product launches from its diverse pipeline.

Confidence in the Future

Dr. Gavin Xia, co-founder and CEO of Alebund, expressed the company’s intent to expedite the global development of its innovative solutions while enhancing its commercial presence in China. He stated, “The successful closing of Series C financing once again proves the importance of the research and development of new therapies for chronic kidney diseases and the confidence from the market in the Alebund team.” With ongoing efforts to improve treatment options for renal disease patients in China and worldwide, Alebund Pharmaceuticals is set to play a vital role in the fight against chronic kidney conditions.

About Alebund Pharmaceuticals

Founded in 2018, Alebund Pharmaceuticals is dedicated to the research, development, production, and commercialization of novel therapies targeting kidney diseases and their complications. The company has worked tirelessly to create a balanced and varied drug candidate portfolio, demonstrating its commitment to addressing critical health challenges faced by patients suffering from chronic kidney diseases. Alebund’s focus on innovation, combined with robust financial backing, positions it to make significant advancements in renal healthcare in the coming years.